Evidence map›Paper›PMID 39336782›Full record

ReviewGenes2024

Transient Myeloproliferative Disorder (TMD), Acute Lymphoblastic Leukemia (ALL), and Juvenile Myelomonocytic Leukemia (JMML) in a Child with Noonan Syndrome: Sequential Occurrence, Single Center Experience, and Review of the Literature.

Marta Arrabito, Nicolò Li Volsi, Manuela La Rosa, Piera Samperi, Giulio Pulvirenti, Emanuela Cannata, Giovanna Russo, Andrea Di Cataldo, Luca Lo Nigro

Abstract readCase ReportsReview
In one paragraph

Review in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. GH Therapy in Non-Growth Hormone-Deficient Children.Children (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta ArrabitoCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.
Nicolò Li VolsiCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.
Manuela La RosaCytogenetic-Cytofluorimetric-Molecular Biology Lab, Center of Pediatric Hematology Oncology, Azienda Policlinico di Catania, Via Santa Sofia 78, 95123 Catania, Italy.
Piera SamperiCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.
Giulio PulvirentiSchool of Pediatrics, University of Catania, 95100 Catania, Italy.
Emanuela CannataCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.
Giovanna RussoCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.ORCID 0000-0001-9369-7473
Andrea Di CataldoCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.ORCID 0000-0002-4509-3066
Luca Lo NigroCenter of Pediatric Hematology Oncology, Azienda Policlinico di Catania, 95100 Catania, Italy.ORCID 0000-0002-2480-1799

Funding

IBISCUS onlus 2022-2023Italian Association for Cancer Research MFAG 2009-2011
6 · The paper itself

Abstract

Noonan syndrome (NS) is an autosomal dominant disorder that varies in severity and can involve multiple organ systems. In approximately 50% of cases, it is caused by missense mutations in the

Indexed as

Leukemia, Myelomonocytic, JuvenileNoonan SyndromeProtein Tyrosine Phosphatase, Non-Receptor Type 11ChildDown SyndromeFemaleGerm-Line MutationHumansLeukemoid ReactionMyeloproliferative DisordersPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanacute lymphoblastic leukemiachildrenhematological diseasesjuvenile myelomonocytic leukemiaNoonan syndromePTPN11 mutation

Identifiers

PMID39336782
PMCPMC11431238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.